Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: A prospective observational study

Scandinavian Journal of Gastroenterology

Volumn 49, Issue 8, 2014, Pages 942-949

  Zissimopoulos, Athanasios ^a   Vradelis, Stergios ^a   Konialis, Manolis ^a   Chadolias, Dimitrios ^a   Bampali, Asimenia ^a   Constantinidis, Theodoros ^a   Efremidou, Eleni ^a   Kouklakis, George ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Chromogranin A; Crohn's disease; IBD; IBS; Ulcerative colitis

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; BIOLOGICAL MARKER; CHROMOGRANIN A; CORTICOSTEROID; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; STEROID; GASTROINTESTINAL AGENT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BIOLOGICAL THERAPY; BLOOD LEVEL; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELIABILITY; REMISSION; TREATMENT RESPONSE; ULCERATIVE COLITIS; BLOOD; COLITIS, ULCERATIVE; DISEASE COURSE; DRUG COMBINATION; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; CHROMOGRANIN A; COLITIS, ULCERATIVE; CROHN DISEASE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL AGENTS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84904429212     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2014.920910     Document Type: Article

References (35)

1. Miller LJ. Gastrointestinal hormones and receptors. In Yamada T, Alpers DH, Kalloo AN, Kaplowitz N, Owyang C, Powell DW, editors. Textbook of gastroenterology. 5th edn. Philadelphia, PA: Lippincott-Williams and Wilkins; 2009. pp 56-85.
2. Schonhoff SE, Giel-Moloney M, Leiter AB. Minireview: development and differentiation of gut endocrine cells. Endocrinology 2004;145:2639-44. (Pubitemid 38686209)
3. HuttnerWB, GerdesHH, Rosa P.The granin (chromogranin/ secretogranin) family. Trends Biochem Sci 1991;16:27-31.
4. Helle K. The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects. Biol Rev Camb Philos Soc 2004;79:769-94. (Pubitemid 39577122)
5. Laurent Taupenot L, Harper KL, OConnor DT. The chromogranin-secretogranin family. N Engl J Med 2003; 348:1134-49. (Pubitemid 36337325)
6. OConnor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986;314:1145-51. (Pubitemid 16138661)
7. Khan WI, Ghia JE. Gut hormones: Emerging role in immune activation and inflammation. Clin Exp Immunol 2010;161: 19-27.
8. Ferrero E, Magni E, Curnis F, Villa A, Ferrero ME, Corti A. Regulation of endothelial cell shape and barrier function by chromogranin A. Ann N Y Acad Sci 2002;971:355-8. (Pubitemid 35305325)
9. Sidhu R, McAlindon ME, Leeds JS, Skilling J, Sanders DS. The role of serum chromogranin A in diarrhoea predominant irritable bowel syndrome. J Gastrointestin Liver Dis 2009;18: 23-6.
10. Sciola V, Massironi S, Conte D, Caprioli F, Ferrero S, Ciafardini C, et al. Plasma chromogranin A in patients with inflammatory bowel disease. Inflamm Bowel Dis 2009;15:867-71.
11. Granberg D, Stridsberg M, Seensalu R, Eriksson B, Lundqvist G, Oberg K, et al. Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1999;84:2712-17. (Pubitemid 30641998)
12. Spadaro A, Ajello A, Morace C, Zirilli A, Darrigo G, Luigiano C, et al. Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits. World J Gastroenterol 2005;11:1987-90. (Pubitemid 40520997)
13. Sidhu R, Drew K, McAlindon ME, Lobo AJ, Sanders DS. Elevated serum chromogranin A in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD): A shared model for pathogenesis? Inflamm Bowel Dis 2009;16:361.
14. Strid H, Simrén M, Lasson A, Isaksson S, Stridsberg M, Ohman L. Fecal chromogranins and secretogranins are increased in patients with ulcerative colitis but are not associated with disease activity. J Crohns Colitis 2013; 7:615-22.
15. Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6:991-1030.
16. Ferrante M, Karmiris K, Newnham E, Siffledeen J, Zelinkova Z, van Assche G, et al. Physician perspectives on unresolved issues in the use of conventional therapy in Crohns disease: results from an international survey and discussion programme. J Crohns Colitis 2012;6:116-31.
17. Ceconi C, Ferrari R, Bachetti T, Opasich C, Volterrani M, Colombo B, et al. Chromogranin A in heart failure. A novel neurohumoral factor and a predictor for mortality. Eur Heart J 2002;23:967-74. (Pubitemid 35203876)
18. Hsiao RJ, Mezger MS, OConnor DT. Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 1990;37:955-64. (Pubitemid 20089229)
19. Massironi S, Fraquelli M, Paggi S, Sangiovanni A, Conte D, Sciola V, et al. Chromogranin A levels in chronic liver disease and hepatocellular carcinoma. Dig Liver Dis 2009;41:31-5.
20. Takiyyuddin MA, Cervenka JH, Hsiao RJ, Barbosa JH, Parmer RJ, OConnor DT. Chromogranin A. Storage and release in hypertension. Hypertension 1990;15:237-46.
21. Sanduleanu S, Stridsberg M, Jonkers D, Hameeteman W, Biemond I, Lundqvist G, et al. Serum gastrin and chromogranin A during medium and long term acid suppressive therapy: A case-control study. Aliment Pharmacol Ther 1999; 13:145-53. (Pubitemid 29090008)
22. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480-91.
23. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. BMJ 1955;2:1041-8.
24. Best WR, Becktel J, Singleton J, Kern F Jr. Development of a Crohns disease activity index. National Cooperative Crohns Disease Study. Gastroenterology 1976;70:439-44.
25. Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, et al. The second European evidence-based Consensus on the diagnosis and management of Crohns disease: definitions and diagnosis. J Crohns Colitis 2010;4:7-27.
26. Dignass A, van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, et al. The second European evidence-based Consensus on the diagnosis and management of Crohns disease: current management. J Crohns Colitis 2010;4:28-62.
27. Moran GW, Pennock J, McLaughlin JT. Enteroendocrine cells in terminal ileal Crohns disease. J Crohns Colitis 2012; 6:871-80.
28. Stenson WF, Snapper SB. Challenges in IBD research: Assessing progress and rethinking the research agenda. Inflamm Bowel Dis 2008;14:687-708.
29. Corti A, Ferrari R, Ceconi C. Chromogranin A and tumor necrosis factor-alpha (TNF) in chronic heart failure. Adv Exp Med Biol 2000;482:351-9. (Pubitemid 32174544)
30. Ferrero E, Scabini S, Magni E, Foglieni C, Belloni D, Colombo B, et al. Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage. FASEB J 2004;18:554-6.
31. Portela-Gomes GM, Grimelius L, Wilander E, Stridsberg M. Granins and granin-related peptides in neuroendocrine tumours. Regul Pept 2010;165:12-20.
32. Di Comite G, Marinosci A, Di Matteo P, Manfredi A, Rovere-Querini P, Baldissera E, et al. Neuroendocrine modulation induced by selective blockade of TNF-alpha in rheumatoid arthritis. Ann N Y Acad Sci 2006;1069:428-37. (Pubitemid 43989886)
33. Di Comite G, Rossi CM, Marinosci A, Lolmede K, Baldissera E, Aiello P, et al. Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-alpha-elicited endothelial activation. J Leukoc Biol 2009;85:81-7.
34. Rumio C, Dusio GF, Colombo B, Gasparri A, Cardani D, Marcucci F, et al. The N-terminal fragment of chromogranin A, vasostatin-1 protects mice from acute or chronic colitis upon oral administration. Dig Dis Sci 2012;57:1227-37.
35. Rozansky DJ, Wu H, Tang K, Parmer RJ, OConnor DT, et al. Glucocorticoid activation of chromogranin A gene expression. Identification and characterization of a novel glucocorticoid response element. J Clin Invest 1994;94: 2357-68.